Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004861 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00004861: Completed Phase 2 study, sponsored by Pfizer.
NCT00004861 is a Phase 2 study that has completed, run by Pfizer. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004861, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or giving drugs in different ways may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of gemcitabine with or without CI-994 in treating patients who have advanced pancreatic cancer.
Interventions
- DRUG gemcitabine hydrochloride
- DRUG tacedinaline
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-10 |
| Est. Completion | 2001-09 |
| Phase | Phase 2 |
What the finished NCT00004861 record still lists
NCT00004861 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which gemcitabine hydrochloride is the first listed.
NCT00004861 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004861 about?
NCT00004861 is a clinical study titled "Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or giving drugs in different ways may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of gemcitabine with or wi...
What is the current status of trial NCT00004861?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-10. Estimated completion is 2001-09.
What interventions are being tested in trial NCT00004861?
The interventions under investigation include: gemcitabine hydrochloride (DRUG), tacedinaline (DRUG).
Who is sponsoring clinical trial NCT00004861?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia